This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Prevenar 13
  • /
  • Study Evaluating the Effiacy of a 13-Valent Pneumo...
Clinical trial

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (CAPITA)

Read time: 1 mins
Last updated:1st Sep 2008

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease
Enrollment: 84496
Study Start Date: September 2008
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)

- Placebo Comparator:
- Experimental: 13-valent pneumococcal conjugate vaccine

Related journal: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults

Category Value
Study start date 2008-09-01

View full details